{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:29:24Z","timestamp":1781659764924,"version":"3.54.5"},"posted":{"date-parts":[[2025,5,8]]},"group-title":"Allergy and Immunology","reference-count":27,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Solid organ transplant (SOT) recipients may have a suboptimal humoral immune response to the coronavirus disease 2019 (COVID-19) vaccine, prompting the need for additional doses of vaccine for immunocompromised patients. However, data regarding immune responses to vaccination specifically in SOT recipients with well controlled HIV are lacking.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a prospective observational cohort single-center study of SOT recipients with and without HIV-1 who had received two doses of mRNA COVID-19 vaccine and were planning to receive additional doses. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding and neutralizing antibody responses were measured at several time points after vaccination.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>Of the 122 SOT recipients enrolled, 44 (36%) were people with HIV (PWH). Overall, 65% (50\/77) of all SOT recipients were seropositive prior to a third vaccine dose. Seropositive SOT recipients with HIV had comparable anti-spike antibody responses at baseline and over time to those without HIV. In addition, HIV status did not impact neutralizing titers in our SOT cohort. Twenty-seven participants were seronegative at baseline; three (11%) were participants with HIV. In addition, 78% (21\/27) of participants seroconverted over the duration of the study; of those who remained seronegative, none had HIV, but all were on an antimetabolites.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>HIV status did not impact longitudinal spike-binding antibody titers or neutralizing titers in SOT recipients.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Research in context<\/jats:title>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Evidence before this study<\/jats:title>\n                  <jats:p>Solid organ transplant (SOT) recipients may mount poor humoral immune responses to COVID-19 vaccines, prompting the need for additional vaccine doses in this patient population. Additional risk factors for poor immune response in this population have been described and include for example, age or use of certain immunosuppressant therapies. However, humoral responses to COVID-19 vaccine in SOT recipients with HIV have not previously been described.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Added value of this study<\/jats:title>\n                  <jats:p>We conducted a prospective observational single center study of solid organ transplant recipients with and without HIV and measured SARS-CoV-2 binding and neutralizing antibody responses longitudinally. Our study results demonstrate that HIV status did not appear to be an additional risk factor that affected the durability of spike-antibody titers or neutralizing titers in SOT recipients over time.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Implications of all the available evidence<\/jats:title>\n                  <jats:p>Well-controlled HIV infection is not an additional risk factor in SOT recipients when assessing responses to COVID-19 vaccine. Future studies should continue to focus on other risk factors, such as type of immunosuppressant therapies and timing of vaccination in relationship to transplant.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.05.07.25327192","type":"posted-content","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T18:05:15Z","timestamp":1746727515000},"source":"Crossref","is-referenced-by-count":1,"title":["Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV"],"prefix":"10.64898","author":[{"given":"Meenakshi M.","family":"Rana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy","family":"Haydel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Gleason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Mauldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander S","family":"Florman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Aberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"van Kesteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Mischka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damodara Rao","family":"Mendu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TITAN Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania","family":"Wajnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cordon-Cardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025051007450785000_2025.05.07.25327192v1.1","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2021.7489"},{"key":"2025051007450785000_2025.05.07.25327192v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2111462"},{"key":"2025051007450785000_2025.05.07.25327192v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2108861"},{"key":"2025051007450785000_2025.05.07.25327192v1.4","doi-asserted-by":"crossref","unstructured":"Karaba, A.H. , et al., A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients. 2021, Infectious Diseases (except HIV\/AIDS).","DOI":"10.1101\/2021.08.11.21261914"},{"issue":"12","key":"2025051007450785000_2025.05.07.25327192v1.5","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1111\/ajt.16814","article-title":"Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept","volume":"21","year":"2021","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"2025051007450785000_2025.05.07.25327192v1.6","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/tri.14029","article-title":"SARS - CoV - 2 vaccination in solid - organ transplant recipients: What the clinician needs to know","volume":"34","year":"2021","journal-title":"Transplant International"},{"issue":"5","key":"2025051007450785000_2025.05.07.25327192v1.7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/microorganisms10051021","article-title":"Evaluation of the Kinetics of Antibody Response to COVID- 19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort","volume":"10","year":"2022","journal-title":"Microorganisms"},{"issue":"4","key":"2025051007450785000_2025.05.07.25327192v1.8","doi-asserted-by":"crossref","first-page":"e226822","DOI":"10.1001\/jamanetworkopen.2022.6822","article-title":"Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis","volume":"5","year":"2022","journal-title":"JAMA Network Open"},{"key":"2025051007450785000_2025.05.07.25327192v1.9","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003824"},{"issue":"1","key":"2025051007450785000_2025.05.07.25327192v1.10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/COH.0000000000000659","article-title":"The interplay between HIV and COVID-19: summary of the data and responses to date","volume":"16","year":"2021","journal-title":"Current Opinion in HIV and AIDS"},{"issue":"1","key":"2025051007450785000_2025.05.07.25327192v1.11","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1093\/cid\/ciac103","article-title":"Prospective Evaluation of Coronavirus Disease 2019 (COVID- 19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)","volume":"75","year":"2022","journal-title":"Clinical Infectious Diseases"},{"issue":"26","key":"2025051007450785000_2025.05.07.25327192v1.12","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1016\/j.vaccine.2022.04.090","article-title":"Covid-19 vaccine immunogenicity in people living with HIV-1","volume":"40","year":"2022","journal-title":"Vaccine"},{"key":"2025051007450785000_2025.05.07.25327192v1.13","doi-asserted-by":"crossref","unstructured":"Brumme, Z.L. , et al., Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. npj Vaccines, 2022. 7(1): p. 28.","DOI":"10.1038\/s41541-022-00452-6"},{"key":"2025051007450785000_2025.05.07.25327192v1.14","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000003527"},{"key":"2025051007450785000_2025.05.07.25327192v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0913-5"},{"key":"2025051007450785000_2025.05.07.25327192v1.16","doi-asserted-by":"publisher","DOI":"10.1002\/cpmc.100"},{"key":"2025051007450785000_2025.05.07.25327192v1.17","doi-asserted-by":"publisher","DOI":"10.1002\/cpmc.108"},{"key":"2025051007450785000_2025.05.07.25327192v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.01.017.23"},{"issue":"8","key":"2025051007450785000_2025.05.07.25327192v1.19","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S2665-9913(23)00160-1","article-title":"Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"2025051007450785000_2025.05.07.25327192v1.20","doi-asserted-by":"crossref","first-page":"e13926","DOI":"10.1111\/tid.13926","article-title":"Humoral and cellular response of COVID- 19 vaccine among solid organ transplant recipients: A systematic review and meta-analysis","volume":"24","year":"2022","journal-title":"Transplant Infectious Disease"},{"issue":"2","key":"2025051007450785000_2025.05.07.25327192v1.21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/ajt.16851","article-title":"Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients","volume":"22","year":"2022","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"2025051007450785000_2025.05.07.25327192v1.22","doi-asserted-by":"crossref","first-page":"e157836","DOI":"10.1172\/jci.insight.157836","article-title":"Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination\u2013specific humoral and cellular immunity in kidney transplant recipients","volume":"7","year":"2022","journal-title":"JCI Insight"},{"issue":"5","key":"2025051007450785000_2025.05.07.25327192v1.23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/ctr.12726","article-title":"Antibody responses to influenza vaccine in pre- and post- lung transplant patients","volume":"30","year":"2016","journal-title":"Clinical Transplantation"},{"issue":"9","key":"2025051007450785000_2025.05.07.25327192v1.24","doi-asserted-by":"crossref","first-page":"e13563","DOI":"10.1111\/ctr.13563","article-title":"The, Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice","volume":"33","author":"Danziger-Isakov, L., D. Kumar, and A.S.T.I.D.C.o.P.","year":"2019","journal-title":"Clinical Transplantation"},{"key":"2025051007450785000_2025.05.07.25327192v1.25","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14478"},{"issue":"4","key":"2025051007450785000_2025.05.07.25327192v1.26","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.kint.2022.07.008","article-title":"COVID-19 morbidity decreases with tixagevimab\u2013cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low- vaccine responders","volume":"102","year":"2022","journal-title":"Kidney International"},{"issue":"5","key":"2025051007450785000_2025.05.07.25327192v1.27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/ajt.16993","article-title":"SARS-CoV-2 antibody testing for transplant recipients: A tool to personalize protection versus COVID-19","volume":"22","year":"2022","journal-title":"American Journal of Transplantation"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.05.07.25327192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:35:40Z","timestamp":1768509340000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.05.07.25327192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1101\/2025.05.07.25327192","relation":{},"subject":[],"published":{"date-parts":[[2025,5,8]]},"subtype":"preprint"}}